Moderna posts a narrower-than-anticipated loss and sharply higher revenue for the first quarter.
By Julie Steenhuysen, Siddhi Mahatole and Mariam Sunny May 1 (Reuters) - Moderna surpassed Wall Street estimates for ...
Vertex Pharmaceuticals halted a cystic fibrosis program in the works with Moderna over lung inflammation concerns. The ...
The results are part of the company’s strategy to “diversify our geographic footprint” and rely less on the US market, Chief ...
Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international marketsReports ...
Moderna reported an increase in revenue during the first quarter, citing higher Covid-19 vaccine sales in international ...
CEO Stéphane Bancel expressed confidence in Moderna’s first quarter, touting the revenue numbers as a sign of the company’s ...
Moderna jumps despite a Q1 loss as strong international vaccine sales drive revenue surge and boost investor sentiment.
Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on ...
Moderna (MRNA) stock jumps after Q1 2026 earnings beat on strong international COVID vaccine sales, despite wider loss driven ...
Moderna surpassed Wall Street estimates for first-quarter revenue on Friday, helped by better-than-expected sales of its COVID-19 vaccine in international markets, sending its shares up nearly 5% in ...
Moderna (MRNA) reports Q1 earnings May 1 premarket—see consensus EPS (-$3.96), revenue ($236M), and estimate revisions to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results